Results 71 to 80 of about 5,328 (181)

Tumor-Agnostic Treatment for Cancer:When How is Better than Where [PDF]

, 2020
In the evolving landscape of precision oncology, genomic characterization of tumor has become crucial in order to move toward a molecular-based therapy for the vast majority of cancers.
D'Angelo, Alberto, Lavacchi, Daniele, Roviello, Giandomenico   +2 more
core   +1 more source

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

The value of personalised medicine from a health economics perspective [PDF]

Personalised medicine (PM) aims to use genetic information to better target healthcare to each individual. PM has been met with excitement and anticipation.
Vellekoop, Heleen
core   +5 more sources

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Entrectinib-induced tubulointerstitial nephritis: a case report

International Journal of Surgery Oncology, 2023
Introduction and importance: Entrectinib has been approved and increasingly administered for the treatment of non-small cell lung cancer, especially with intracranial metastasis. Although previous clinical studies have confirmed its safety, disproportionality analysis showed unusually high potential adverse renal effects.
Márk Stempler, Deján Dobi, Nóra Ledó
openaire   +1 more source

Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer [PDF]

, 2015
In metastatic colorectal cancer (CRC), actionable genetic lesions represent potential clinical opportunities. NTRK1, 2, and 3 gene rearrangements encode oncogenic fusions of the tropomyosin-receptor kinase (TRK) family of receptor tyrosine kinases in ...
Alzani, Rachele, Amatu, Alessio, Ardini, Elena, Banfi, Patrizia, Bardelli, Alberto, Bonazzina, Erica, Bosotti, Roberta, Davite, Cristina, Galvani, Arturo, Hornby, Zachary, Isacchi, Antonella, Leone, Antonella, Lim, Jonathan, Luo, David, Marrapese, Giovanna, Martignoni, Marcella, Misale, Sandra, Palmeri, Laura, Raddrizzani, Laura, Sartore Bianchi, Andrea, Siena, Salvatore, Somaschini, Alessio, Valtorta, Emanuele, Vanzulli, Angelo, Veronese, Silvio   +24 more
core   +2 more sources

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib

Thoracic Cancer, 2021
ROS1 rearrangements are found in 1–2% of patients with non‐small‐cell lung cancer. The detection of the rearrangements is crucial since clinically effective molecular targeted drugs are available for them.
Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima, Tetsuya Shiomi   +10 more
doaj   +1 more source

NTRK-A narrative review

Cancer Research, Statistics, and Treatment, 2021
Lung cancer diagnostics and therapeutics have witnessed a paradigm shift in the last decade because of the discovery of targetable biomarkers and rapid approvals of the corresponding targeted therapies.
Ullas Batra, Shrinidhi Nathany, Mansi Sharma   +2 more
doaj   +1 more source

Personalizing therapies over the course of hormone receptor‐positive/HER2‐negative metastatic breast cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
ABSTRACT The hormone receptor (HR)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer subtype accounts for most early and metastatic breast cancer (MBC) cases. HR‐positive/HER2‐negative MBC is characterized by a relatively prolonged, although variable, disease course and substantial intertumoral and intratumoral ...
Akshara Singareeka Raghavendra, Senthil Damodaran, Carlos H. Barcenas, Suzanne A. Fuqua, Rachel M. Layman, Debu Tripathy   +5 more
wiley   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Pediatric Patients

Current Oncology, 2021
Neurotrophic tyrosine receptor kinase gene fusions (NTRK) are oncogenic drivers present at a low frequency in most tumour types (80%) in a small number of rare tumours (e.g., infantile fibrosarcoma [IFS]) and considered mutually exclusive with other ...
Sébastien Perreault, Rose Chami, Rebecca J. Deyell, Dina El Demellawy, Benjamin Ellezam, Nada Jabado, Daniel A. Morgenstern, Aru Narendran, Poul H. B. Sorensen, Jonathan D. Wasserman, Stephen Yip   +10 more
doaj   +1 more source